Yale New Haven Hospital, Yale University, New Haven, CT. RATIONALE: Immune-related adverse events (IRAEs) associated with checkpoint inhibitors can affect almost any organ system and certain patients likely have a predilection for immune dysregulation. Current guidelines for oncologists suggest treating IRAEs with systemic steroids. However, steroids are not likely to be the most efficacious treatment modality for certain IRAEs, and in some cases, patients may require more directed treatment regimens.
METHODS:
The following patients were seen in our Smilow Cancer Center Immunology Clinic. An immune evaluation was done, including cytokine panels, immune deficiency flow cytometry, and inflammatory markers. Case 1: A 61-year-old gentleman undergoing treatment for stage IV esophageal carcinoma received treatment with anti-PD-1 immunotherapy. When he developed a rash, his oncologist stopped immunotherapy and began prednisone. He was diagnosed with psoriasis and initiated on a retinoid. Case 2: A 44-year-old-woman with stage I breast cancer treated with anti-PD-L1 immunotherapy developed severe parotitis, duodenitis, colitis, and b-cell lymphopenia. She had an incomplete response to systemic steroids, ultimately requiring infliximab and methotrexate. METHODS: A Continuing Medical Education (CME) activity was developed to increase pneumococcal and influenza rates in adults with chronic inflammatory conditions. Educational content incorporated updated CDC guidelines regarding pneumococcal vaccination. This activity was disseminated to AAAAI members in online and print formats, and to a single academic rheumatology, allergy, and immunology division in a live, interactive format. Descriptive statistics were used to evaluate confidence in vaccination practices and perception of the activity. Paired t-test was used to evaluate pre-and post-activity knowledge in a subset of participants. RESULTS: Of 265 participants who completed the activity, 94% subsequently indicated confidence in applying current guidelines for pneumococcal and influenza vaccination and 85% perceived the quality of the content and format to be very good to excellent. Fifty-seven percent planned to change their practice. Of those who did not plan to change their practice, 61% felt that their current practice behaviors were reinforced. In 21 participants, knowledge was significantly increased after completing the activity (p5.0001), with a pre-test mean percent of 75% (SD 11.6%, range 70-80%) versus a post-test mean of percent of 89% (SD 11.1%, range 85-95%). CONCLUSIONS: This CME module was effective in increasing clinicians' knowledge and confidence in vaccination for adults with chronic inflammatory conditions. Quality improvement endeavors can incorporate CME activities such as this one to increase vaccination rates.
